Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ATHENA (A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)

NCT03522246 is registered in ClinicalTrials.gov with pharmaand GmbH as lead sponsor.

NCT NCT03522246
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03522246 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ATHENA (A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)
Lead sponsor
pharmaand GmbH
Phase
Phase 3
Overall status
Active, not recruiting
Start date
May 14, 2018
Completion date
December 30, 2030
Enrollment
1,097 (actual)
Sites
238

Conditions

As the registry lists them; a condition with its own page is linked.

complete response, epithelial ovarian cancer, fallopian tube cancer, figo stage iii-iv, newly diagnosed, partial response, primary peritoneal